Alexander A. Semenkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander A. Semenkin has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina N. Loginova
Omsk State Medical University
4 shared publications - Alexey Nikolaevich Meshkov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
3 shared publications - Galina Nechaeva
Omsk State Medical University
3 shared publications - Inna Viktorovna Druk
Omsk State Medical University
3 shared publications - Albert S. Galyavich
Kazan State Medical University
2 shared publications - Alexander E. Filippov
Saint Petersburg State University
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (3) , 263-277
Arterial stiffness as a therapeutic target: from pathophysiological mechanisms to the selection of antihypertensive agents
This review summarizes current understanding of the role of arterial stiffness in the development of cardiovascular diseases and its clinical implications. The article provides a detailed analysis of the main pathophysiological mechanisms of vascular remodeling underlying the increase in arterial wall rigidity. The contribution of key risk factors to the increase in arterial stiffness is demonstrated, and the prognostic significance of this parameter is discussed. Special attention is paid to the relationship between arterial stiffness and blood pressure parameters, including blood pressure variability. The problem of comorbidity in patients with hypertension is addressed, including the impact of chronic pain syndrome and nonsteroidal anti-inflammatory drugs on the vascular wall and the effectiveness of antihypertensive therapy. The potential of different classes of antihypertensive agents is analyzed in terms of their ability not only to control blood pressure levels but also to influence the elastic properties of arteries. Approaches to the selection of therapeutic strategies aimed at reducing vascular stiffness are considered, with the goal of improving long-term prognosis in patients with high cardiovascular risk.
- 25 September 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (3) , 263-277
Open AccessArterial stiffness as a therapeutic target: from pathophysiological mechanisms to the selection of antihypertensive agents
This review summarizes current understanding of the role of arterial stiffness in the development of cardiovascular diseases and its clinical implications. The article provides a detailed analysis of the main pathophysiological mechanisms of vascular remodeling underlying the increase in arterial wall rigidity. The contribution of key risk factors to the increase in arterial stiffness is demonstrated, and the prognostic significance of this parameter is discussed. Special attention is paid to the relationship between arterial stiffness and blood pressure parameters, including blood pressure variability. The problem of comorbidity in patients with hypertension is addressed, including the impact of chronic pain syndrome and nonsteroidal anti-inflammatory drugs on the vascular wall and the effectiveness of antihypertensive therapy. The potential of different classes of antihypertensive agents is analyzed in terms of their ability not only to control blood pressure levels but also to influence the elastic properties of arteries. Approaches to the selection of therapeutic strategies aimed at reducing vascular stiffness are considered, with the goal of improving long-term prognosis in patients with high cardiovascular risk.
- Open Access
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Hypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Open AccessHypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- Open Access
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Open AccessEurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- Open Access
- 15 March 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2) , 6240
Hypertriglyceridemia — current status of the problem. Part II: primary and secondary hypertriglyceridemias, treatment options
Hypertriglyceridemias are a heterogeneous group of pathologies differing in the mechanisms of triglyceride-rich lipoprotein increase, the composition of lipoproteins and related risks. This review article presents information on the profile and pathogenesis of various primary and secondary hypertriglyceridemias, as well as describes current potential of genetic diagnostics, drug and non-drug correction.
- 15 March 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2) , 6240
Open AccessHypertriglyceridemia — current status of the problem. Part II: primary and secondary hypertriglyceridemias, treatment options
Hypertriglyceridemias are a heterogeneous group of pathologies differing in the mechanisms of triglyceride-rich lipoprotein increase, the composition of lipoproteins and related risks. This review article presents information on the profile and pathogenesis of various primary and secondary hypertriglyceridemias, as well as describes current potential of genetic diagnostics, drug and non-drug correction.
- Open Access
- 6 December 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (1) , 6179
Hypertriglyceridemia — current status of the problem. Part I: risks, physiology and pathophysiological aspects, classification and diagnostic problems
Numerous studies demonstrate an independent relationship between an increase in the blood content of triglyceride-rich particles and the risk of atherosclerotic cardiovascular diseases and acute pancreatitis. This review article presents in detail aspects of the pathogenesis of various types of primary and most relevant secondary hypertriglyceridemias (HTGs). Classifications are provided depending on the etiology, phenotype of dyslipidemia and severity. Approaches to HTG diagnosis are described. Special attention is paid to the potential of HTG therapy.
- 6 December 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (1) , 6179
Open AccessHypertriglyceridemia — current status of the problem. Part I: risks, physiology and pathophysiological aspects, classification and diagnostic problems
Numerous studies demonstrate an independent relationship between an increase in the blood content of triglyceride-rich particles and the risk of atherosclerotic cardiovascular diseases and acute pancreatitis. This review article presents in detail aspects of the pathogenesis of various types of primary and most relevant secondary hypertriglyceridemias (HTGs). Classifications are provided depending on the etiology, phenotype of dyslipidemia and severity. Approaches to HTG diagnosis are described. Special attention is paid to the potential of HTG therapy.
- Open Access
- 25 July 2023
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 3,p. 69-73
Omics technologies in the diagnosis of oncological diseases
High mortality and disability from cancer remains one of the important and unresolved issues of modern medicine. Experts of WHO consider, that cancer is the second leading cause of death worldwide. Approximately 9 million people die of cancer each year, and more than 14 million are diagnosed with cancer. At the same time, according to Russian epidemiology, there is a trend to increase of cases of cancer, including people of young working age, and there is no reliable, verified information about the causes and mechanisms of development of tumor cells. The patient may begin to complain too late, so it is not always possible to suspect this and prevent the diseases. Many research centers and clinics are concerned about this problem and are deeply involved in solving it. To date, a promising direction in the diagnosis of oncological diseases are omics technologies, which are being studied, tested and gradually introduced into modern medicine. According to scientists, the future of healthcare lies with omics technologies, since they allow studying the whole patient’s genotype, which will allow to suggest a person’s predisposition to a particular disease very early, develop methods of correction and prevention, and select the most effective methods of treatment. The purpose of this review is to systematize domestic and foreign data on the current results of the use of omics technologies in the early diagnosis of oncological diseases.
- 25 July 2023
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 3,p. 69-73
Open AccessOmics technologies in the diagnosis of oncological diseases
High mortality and disability from cancer remains one of the important and unresolved issues of modern medicine. Experts of WHO consider, that cancer is the second leading cause of death worldwide. Approximately 9 million people die of cancer each year, and more than 14 million are diagnosed with cancer. At the same time, according to Russian epidemiology, there is a trend to increase of cases of cancer, including people of young working age, and there is no reliable, verified information about the causes and mechanisms of development of tumor cells. The patient may begin to complain too late, so it is not always possible to suspect this and prevent the diseases. Many research centers and clinics are concerned about this problem and are deeply involved in solving it. To date, a promising direction in the diagnosis of oncological diseases are omics technologies, which are being studied, tested and gradually introduced into modern medicine. According to scientists, the future of healthcare lies with omics technologies, since they allow studying the whole patient’s genotype, which will allow to suggest a person’s predisposition to a particular disease very early, develop methods of correction and prevention, and select the most effective methods of treatment. The purpose of this review is to systematize domestic and foreign data on the current results of the use of omics technologies in the early diagnosis of oncological diseases.
- Open Access
- 14 May 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (2) , 138-149
Hypertensive heart: from left ventricular hypertrophy to chronic heart failure
Objective. The purpose of this review is to highlight the pathophysiological mechanisms of the sequential formation of left ventricular hypertrophy (LVH), left ventricular dysfunction and chronic heart failure (CHF) in patients with hypertension (HTN), diagnostic and therapeutical issues of CHF with both reduced and preserved ejection fraction (EF). HTN is the main risk factor for cardiovascular diseases and is accompanied by damage of target organs, among which LVH is of particular importance. On the one hand, development of LVH is the consequence of increased load on the heart muscle and neurohumoral stimuli, and on the other hand, it is an independent risk factor for myocardial infarction, stroke, cardiac arrhythmias and CHF. HTN precedes newly developed heart failure in 91 % of patients with a predominance of CHF with a preserved EF according to the Framingham Heart Study. To date, different drugs can improve the prognosis of patients with HTN, CHF with reduced EF and to induce LVH regression. However, the issues of effective treatment of patients with CHF with preserved EF are still insufficiently studied.
- 14 May 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (2) , 138-149
Open AccessHypertensive heart: from left ventricular hypertrophy to chronic heart failure
Objective. The purpose of this review is to highlight the pathophysiological mechanisms of the sequential formation of left ventricular hypertrophy (LVH), left ventricular dysfunction and chronic heart failure (CHF) in patients with hypertension (HTN), diagnostic and therapeutical issues of CHF with both reduced and preserved ejection fraction (EF). HTN is the main risk factor for cardiovascular diseases and is accompanied by damage of target organs, among which LVH is of particular importance. On the one hand, development of LVH is the consequence of increased load on the heart muscle and neurohumoral stimuli, and on the other hand, it is an independent risk factor for myocardial infarction, stroke, cardiac arrhythmias and CHF. HTN precedes newly developed heart failure in 91 % of patients with a predominance of CHF with a preserved EF according to the Framingham Heart Study. To date, different drugs can improve the prognosis of patients with HTN, CHF with reduced EF and to induce LVH regression. However, the issues of effective treatment of patients with CHF with preserved EF are still insufficiently studied.
- Open Access
- 7 October 2022
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 116-128
Risk factors of malignancy
Prevention strategies aim to change environmental and lifestyle risk factors that contribute to the development of cancer. Screening detects abnormalities before they become clinically apparent, allowing intervention either before cancer develops or at an early stage when treatment is most likely to be effective. Despite reliable data on factors that reduce the risk of neoplasms, in routine clinical practice, the effectiveness of cancer prevention is still not high enough. This determines the high importance of the topic of this review, which summarizes the current scientific data on risk factors for the development of oncopathology and ways to influence them. Such risk factors as lifestyle, alcohol and tobacco use, physical activity, nutrition and other environmental factors are considered. A large role is given to infections, which is also considered in this review. The article highlights the intake of vitamins and microelements for the purpose of cancer prevention, as well as the influence of certain drugs taken to treat non-oncological diseases on the development of oncopathology. The purpose of the review is to present an analysis of current literature data on the methods of cancer prevention.
- 7 October 2022
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 116-128
Open AccessRisk factors of malignancy
Prevention strategies aim to change environmental and lifestyle risk factors that contribute to the development of cancer. Screening detects abnormalities before they become clinically apparent, allowing intervention either before cancer develops or at an early stage when treatment is most likely to be effective. Despite reliable data on factors that reduce the risk of neoplasms, in routine clinical practice, the effectiveness of cancer prevention is still not high enough. This determines the high importance of the topic of this review, which summarizes the current scientific data on risk factors for the development of oncopathology and ways to influence them. Such risk factors as lifestyle, alcohol and tobacco use, physical activity, nutrition and other environmental factors are considered. A large role is given to infections, which is also considered in this review. The article highlights the intake of vitamins and microelements for the purpose of cancer prevention, as well as the influence of certain drugs taken to treat non-oncological diseases on the development of oncopathology. The purpose of the review is to present an analysis of current literature data on the methods of cancer prevention.
- Open Access
- 7 October 2022
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 222-228
Targeted therapy in oncology
The aim of the review is to highlight the principle of action, effectiveness and prospects for the development of targeted therapy in the treatment of patients with malignant neoplasms based on recent clinical studies. Thanks to the active study of tumor biology, specific target molecules have been discovered and it has become possible to target tumor cells with targeted drugs. Today, targeted drugs are used in the treatment of malignant tumors of various organs and continue to demonstrate their effectiveness, improve overall survival and progression-free time, compared with previous standards of treatment.
- 7 October 2022
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 222-228
Open AccessTargeted therapy in oncology
The aim of the review is to highlight the principle of action, effectiveness and prospects for the development of targeted therapy in the treatment of patients with malignant neoplasms based on recent clinical studies. Thanks to the active study of tumor biology, specific target molecules have been discovered and it has become possible to target tumor cells with targeted drugs. Today, targeted drugs are used in the treatment of malignant tumors of various organs and continue to demonstrate their effectiveness, improve overall survival and progression-free time, compared with previous standards of treatment.
- 9 April 2021
- Published by Bionika Media in Therapy
- Vol. 3_2021
Lung and skin multiple primary cancer: clinical case description
- 9 April 2021
- Published by Bionika Media in Therapy
- Vol. 3_2021
Lung and skin multiple primary cancer: clinical case description